Arecor Therapeutics (LON:AREC) Stock Falls 1.5% – Should You Sell?

Shares of Arecor Therapeutics plc (LON:AREC) fell 1.5% during trading on Friday. The stock traded as low as GBX 81.25 and last traded at GBX 81.25. Approximately 1,465 shares traded hands during mid-day trading, a decline of 94% from the average session volume of 26,433 shares. The stock had previously closed at GBX 82.50.

Arecor Therapeutics Price Performance

The stock has a market cap of £30.68 million, a price-to-earnings ratio of 81.25 and a beta of -0.18. The stock’s 50 day moving average price is GBX 77.26 and its two-hundred day moving average price is GBX 69. The company has a quick ratio of 6.24, a current ratio of 4.29 and a debt-to-equity ratio of 1.55.

Arecor Therapeutics (LON:AREC) last issued its earnings results on Thursday, October 1st. The company reported GBX (8) earnings per share (EPS) for the quarter. Arecor Therapeutics had a positive return on equity of 3.75% and a negative net margin of 200.00%. Equities research analysts forecast that Arecor Therapeutics plc will post -0.35 EPS for the current fiscal year.

Arecor Therapeutics Company Profile

Arecor Therapeutics plc (AIM: AREC) is a clinical-stage biotech company developing superior therapeutics that can reduce treatment burden and improve outcomes for people living with diabetes, obesity and other cardiometabolic diseases.

Lead product, AT278, is the only ultra-concentrated (500U/mL) ultra-rapid-acting insulin in development. Arecor has signed an initial strategic partnership with Sequel Med Tech, a leading automated insulin delivery (AID) system company to co-develop AT278 in combination with Sequel’s twiist™ AID system.